臨床検査51巻8号

2007年08月発行

今月の主題 ヒト乳頭腫ウイルス(HPV)と子宮頸癌 総説

HPV感染の関与する子宮頸癌の臨床と疫学

著者： 山川洋光¹ 今野良¹ 鈴木光明²

所属機関： ¹自治医科大学附属大宮医療センター婦人科 ²自治医科大学産科婦人科

ページ範囲：P.823 - P.829

　子宮頸癌の主な原因は，高リスク型ヒトパピローマウイルス(human papillomavirus;HPV)の持続感染である．したがって，HPVの感染を予防できれば，その発症を抑えられることにつながる．子宮頸癌は他の癌と異なり，定期的な検診で前癌病変のうちに発見することが可能であるため，細胞診やHPVテストといったスクリーニングによる早期発見が重要である．さらに，最近，原因となるHPV感染そのものを防御するワクチンによるHPV感染予防が臨床応用された．

参考文献

1) 今野良，鈴木光明，大和田倫孝，他：子宮頸がん検診の30歳未満若年層への拡大．産科と婦人科 71：1907-1913, 2004

2) 今野良，永井堅，永井宏，他：子宮癌検診．診断と治療 93：1575-1582, 2005

3) Durst M, Gissmann L, Ikenberg H, et al：A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci 80：3812-3815, 1983

4) zur Hausen H：Viruses in human cansers. Science 254：1176-1273, 1991

5) Walboomers JM, Jacobs MV, Manos MM, et al：Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189：12-19, 1999

6) Koutsky L：Epidemiology of genital human papillomavirus infection. Am J Med 102：3-8, 1997

7) Crum CP, Abbott DW, Quade BJ：Cervical cancer screening：from the papanicolaou smear to the vaccine era. J Clin Oncol 21：224-230, 2003

8) Ho GY, Bierman R, Beardsley L, et al：Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338：423-428, 1998

9) Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al：Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening：a prospective study. Lancet 354：20-25, 1999

10) Koutsky LA, Ault KA, Wheeler CM, et al：A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347：1645-1651, 2002

11) Munoz N, Bosch FX, Castellsague X, et al：Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111：278-285, 2004

12) Smith JS, Lindsay L, Keys J, et al：HPV type distribution in invasive cervical cancer and high-grade cervical neoplasia：an update of meta-analyses and identification of global data gaps. Br J Cancer, submitted

13) Nakagawa S, Yoshikawa H, Onda T, et al：Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 78：1935-1941, 1996

14) 沖明典：コホート研究に基づくCINⅠ/Ⅱの管理方針と高危険群の抽出．日産婦誌 58：323-324(S175-176)，2006

15) Asato T, Maehama T, Nagai Y, et al：A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 189：1829-1832, 2004

16) Maehama T：Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. Infect Dis Obstet Gynecol 13：77-80, 2005

17) Bosch FX, de Sanjose S：Chapter 1：Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31：3-13, 2003

18) Lorincz AT, Reid R, Jenson AB, et al：Human papillomavirus infection of the uterine cervix：relative risk association of 15 common anogenital types. Obstet Gynecol 79：328-337, 1992

19) Melnikow J, Nuovo J, Willan AR, et al：Natural history of cervical squamous intraepithelial lesions：a meta-analysis. Obstet Gynecol 92：727-735, 1998

20) Clifford G, Franceschi S, Diaz M, et al：Chapter 3：HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 (Suppl 3)：S26-34, 2006

21) Yoshikawa H, Nagata C, Noda K, et al：Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer 80：621-624, 1999

22) Oyama M, Iwasaka T, Nagata C, et al：Prognostic factors associated with the clinical outcome of cervical intraepithelial neoplasia：a cohort study in Japan. Cancer Lett 192：171-179, 2003

23) 田㔟亨，佐藤信二：子宮頸部と発癌―腺癌．産婦の実際 50：947-956, 2001

24) Castellsague X, Diaz M, de Sanjose S, et al：Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors：implications for screening and prevention. J Natl Cancer Inst 98：303-315, 2006

25) Andersson S, Rylander E, Larsson B, et al：The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37：246-250, 2001

and invasive adenocarcinomas of the cervix uteri. Virchows Arch 437：491-500, 2000

27) Anciaux D, Lawrence WD, Gregoire L, et al：Glandular lesions of the uterine cervix：prognostic implications of human papillomavirus status. Int J Gynecol Pathol 16：103-110, 1997

28) Tase T, Okagaki T, Clark BA, et al：Human papillomavirus DNA in glandular dysplasia and microglandular hyperplasia：presumed precursors of adenocarcinoma of the uterine cervix. Obstet Gynecol 73：1005-1008, 1989

29) Lazcano-Ponce E, Herrero R, Munoz N, et al：Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91：412-420, 2001

30) Molano M, Posso H, Weiderpass E, et al：HPV Study Group HPV Study. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 87：324-333, 2002

31) Harper DM, Franco EL, Wheeler C, et al：GlaxoSmithKline HPV Vaccine Study Group：Lancet 364：1757-1765, 2004

32) Villa LL, Costa RL, Petta CA, et al：Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women：a randomised double-blind placebo-controlled multicentre phase Ⅱ efficacy trial. Lancet Oncol 6：271-278, 2005

33) Mao C, Koutsky LA, Ault KA, et al：Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia：a randomized controlled trial. Obstet Gynecol 107：18-27, 2006

34) Harper DM, Franco EL, Wheeler CM, et al：Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18：follow-up from a randomised control trial. Lancet 367：1247-1255, 2006